Eidos Therapeutics, Inc. focuses on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR). Its product include the AG10, an orally-administered small molecule designed to potently stabilize TTR, suggesting a treatment with the potential to halt the progression of ATTR. The company was founded by Graef Isabella and Alhamadsheh Mamoun on August 6, 2013 and is headquartered in San Francisco, CA.
Company profile
Ticker
EIDX
Exchange
Website
CEO
Neil Kumar
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
463733671
EIDX stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
5 Feb 21
EFFECT
Notice of effectiveness
28 Jan 21
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Jan 21
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Jan 21
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Jan 21
POS AM
Prospectus update (post-effective amendment)
26 Jan 21
25-NSE
Exchange delisting
26 Jan 21
8-K
Entry into a Material Definitive Agreement
26 Jan 21
8-K
Submission of Matters to a Vote of Security Holders
20 Jan 21
425
Business combination disclosure
13 Jan 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 20 | Jun 20 | Mar 20 | Sep 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 19 | Dec 18 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 147.33 mm | 147.33 mm | 147.33 mm | 147.33 mm | 147.33 mm | 147.33 mm |
Cash burn (monthly) | 9.16 mm | (no burn) | 9.80 mm | 6.19 mm | 9.21 mm | 4.80 mm |
Cash used (since last report) | 393.49 mm | n/a | 420.81 mm | 265.77 mm | 395.49 mm | 206.01 mm |
Cash remaining | -246.16 mm | n/a | -273.48 mm | -118.44 mm | -248.17 mm | -58.68 mm |
Runway (months of cash) | -26.9 | n/a | -27.9 | -19.1 | -26.9 | -12.2 |
Institutional ownership, Q1 2023
0.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 1.00 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
BBIO BridgeBio Pharma | 1.00 k | $0.00 |